Search Results

There are 5464 results for: content related to: In routine clinical practice, few physicians use early viral kinetics to guide HCV dual therapy treatment decisions

  1. You have full text access to this OnlineOpen article
    Ribavirin revisited in the era of direct-acting antiviral therapy for hepatitis C virus infection

    Liver International

    Volume 37, Issue 1, January 2017, Pages: 5–18, Jordan J. Feld, Ira M. Jacobson, Mark S. Sulkowski, Fred Poordad, Fernando Tatsch and Jean-Michel Pawlotsky

    Version of Record online : 29 SEP 2016, DOI: 10.1111/liv.13212

  2. On-treatment prediction of sustained response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B patients

    Liver International

    Volume 35, Issue 5, May 2015, Pages: 1540–1548, Ioannis Goulis, Stylianos Karatapanis, Evangelos Akriviadis, Melanie Deutsch, George N. Dalekos, Maria Raptopoulou-Gigi, Konstantinos Mimidis, George Germanidis, Christos Drakoulis, Christos Triantos, Elias Zintzaras, Georgios Bakalos and George Papatheodoridis

    Version of Record online : 20 NOV 2014, DOI: 10.1111/liv.12725

  3. DAUPHINE: a randomized phase II study of danoprevir/ritonavir plus peginterferon alpha-2a/ribavirin in HCV genotypes 1 or 4

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 108–119, Gregory Everson, Curtis Cooper, Christophe Hézode, Mitchell L. Shiffman, Eric Yoshida, Teresita Beltran-Jaramillo, Pietro Andreone, Savino Bruno, Peter Ferenci, Stefan Zeuzem, Michael Brunda, Sophie Le Pogam, Isabel Nájera, Julian Zhou, Mercidita T. Navarro, Athina Voulgari, Nancy S. Shulman and Ellen S. Yetzer

    Version of Record online : 12 FEB 2014, DOI: 10.1111/liv.12471

  4. Mericitabine and ritonavir-boosted danoprevir with or without ribavirin in treatment-naive HCV genotype 1 patients: INFORM-SVR study

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 79–89, Edward J. Gane, Paul J. Pockros, Stefan Zeuzem, Patrick Marcellin, Anna Shikhman, Coen Bernaards, Julian Zhou, Ellen S. Yetzer, Rosa Ballester, Cindy Dwyer, Xiao Tong, Isabel Nájera, Anne Bertasso, Janet Hammond, Amy Kindrick, Peter N. Morcos, Patrick Smith, Saray Stancic and Nancy S. Shulman

    Version of Record online : 18 JUN 2014, DOI: 10.1111/liv.12588

  5. Low-density lipoprotein and other predictors of response with telaprevir-based therapy in treatment-experienced HCV genotype 1 patients: REALIZE study

    Liver International

    Volume 35, Issue 2, February 2015, Pages: 448–454, Thomas Berg, Pietro Andreone, Stanislas Pol, Stuart Roberts, Zobair Younossi, Moises Diago, Eric J. Lawitz, Roberto Focaccia, Graham R. Foster, Andrzej Horban, Isabelle Lonjon-Domanec, Ralph DeMasi, Gaston Picchio, Donghan Luo, Sandra De Meyer and Stefan Zeuzem

    Version of Record online : 11 NOV 2014, DOI: 10.1111/liv.12703

  6. A tool for selecting patients with a high probability of sustained virological response to peginterferon alfa-2a (40kD)/ribavirin

    Liver International

    Volume 34, Issue 10, November 2014, Pages: 1550–1559, Peter Ferenci, Rodrigo Aires, Ioan Ancuta, Andrew Arohnson, Hugo Cheinquer, Dragan Delic, Michael Gschwantler, Dominique Larrey, Ludovico Tallarico, Manuela Schmitz, Fernando Tatsch and Denis Ouzan

    Version of Record online : 9 JAN 2014, DOI: 10.1111/liv.12439

  7. You have free access to this content
    Peginterferon alpha-2a versus peginterferon alpha-2b for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk and Christian Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005642.pub3

  8. You have free access to this content
    Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C

    Intervention Review

    The Cochrane Library

    Goran Hauser, Tahany Awad, Jesper Brok, Kristian Thorlund, Davor Štimac, Mahasen Mabrouk, Christian Gluud and Lise Lotte Gluud

    Published Online : 28 FEB 2014, DOI: 10.1002/14651858.CD005441.pub3

  9. Safety of peginterferon alfa-2a plus ribavirin in a large multinational cohort of chronic hepatitis C patients

    Liver International

    Volume 32, Issue 8, September 2012, Pages: 1270–1277, Samuel S. Lee, Stuart K. Roberts, Hanna Berak, Geoffrey M. Dusheiko, Hugh A. Harley, Edward J. Gane, Petr Husa, Yves J. Horsmans, Stephanos J. Hadziyannis, E. Jenny Heathcote, Diethelm Messinger, Fernando Tatsch, Kwang-Hyub Han and Peter Ferenci

    Version of Record online : 24 MAY 2012, DOI: 10.1111/j.1478-3231.2012.02819.x

  10. Omega-3 fatty acids and/or fluvastatin in hepatitis C prior non-responders to combination antiviral therapy – a pilot randomised clinical trial

    Liver International

    Volume 34, Issue 5, May 2014, Pages: 737–747, David A. Sheridan, Simon H. Bridge, Mary M. E. Crossey, Daniel J. Felmlee, Fiona I. Fenwick, Howard C. Thomas, R. Dermot G. Neely, Simon D. Taylor-Robinson and Margaret F. Bassendine

    Version of Record online : 14 OCT 2013, DOI: 10.1111/liv.12316

  11. You have full text access to this OnlineOpen article
    Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia

    Liver International

    Volume 35, Issue 11, November 2015, Pages: 2358–2362, Xavier Forns, Fred Poordad, Marcos Pedrosa, Marina Berenguer, Heiner Wedemeyer, Peter Ferenci, Mitchell L. Shiffman, Michael W. Fried, Sandra Lovell, Roger Trinh, Juan Carlos Lopez-Talavera and Gregory Everson

    Version of Record online : 6 SEP 2015, DOI: 10.1111/liv.12931

  12. Daclatasvir + asunaprevir + beclabuvir ± ribavirin for chronic HCV genotype 1-infected treatment-naive patients

    Liver International

    Volume 36, Issue 2, February 2016, Pages: 189–197, Gregory T. Everson, Karen D. Sims, Paul J. Thuluvath, Eric Lawitz, Tarek Hassanein, Maribel Rodriguez-Torres, Tadesse Desta, Trevor Hawkins, James M. Levin, Federico Hinestrosa, Vinod Rustgi, Howard Schwartz, Zobair Younossi, Lynn Webster, Norman Gitlin, Timothy Eley, Shu-Pang Huang, Fiona McPhee, Dennis M. Grasela and David F. Gardiner

    Version of Record online : 6 DEC 2015, DOI: 10.1111/liv.12964

  13. Improved pharmacodynamics and pharmacokinetics after i.v. application of peginterferon alfa-2a in hepatitis C null responders

    Liver International

    Volume 35, Issue 10, October 2015, Pages: 2275–2284, Balazs Fülöp, Michael Biermer, Markus Cornberg, Heiner Wedemeyer, Kerstin Port, Renate Heyne, Stefan Zeuzem, Kai-Henrik Peiffer, Tania Welzel, Adam Herber, Peter Buggisch, Christoph Moser, Sabine Stoll, Ulrich Alshuth and Thomas Berg

    Version of Record online : 20 APR 2015, DOI: 10.1111/liv.12832

  14. Antiviral treatment for chronic hepatitis C in patients with human immunodeficiency virus

    Intervention Review

    The Cochrane Library

    Alfonso Iorio, Emanuela Marchesini, Tahany Awad and Lise Lotte Gluud

    Published Online : 20 JAN 2010, DOI: 10.1002/14651858.CD004888.pub2

  15. You have free access to this content
    The role of HBsAg quantification for monitoring natural history and treatment outcome

    Liver International

    Volume 33, Issue s1, February 2013, Pages: 125–132, Michelle Martinot-Peignoux, Martine Lapalus, Tarik Asselah and Patrick Marcellin

    Version of Record online : 3 JAN 2013, DOI: 10.1111/liv.12075

  16. You have free access to this content
    The treatment of chronic hepatitis C in HIV-infected patients: a meta-analysis

    HIV Medicine

    Volume 8, Issue 5, July 2007, Pages: 312–321, AI Kim, A Dorn, R Bouajram and S Saab

    Version of Record online : 7 JUN 2007, DOI: 10.1111/j.1468-1293.2007.00476.x

  17. High MIG (CXCL9) plasma levels favours response to peginterferon and ribavirin in HCV-infected patients regardless of DPP4 activity

    Liver International

    Volume 36, Issue 3, March 2016, Pages: 344–352, Susanne Johansson, Willem Talloen, Marianne Tuefferd, Jama Darling, Gregory Fanning, Michael W. Fried and Jeroen Aerssens

    Version of Record online : 6 SEP 2015, DOI: 10.1111/liv.12932

  18. You have free access to this content
    Pharmacodynamics of peginterferon alfa-2a and peginterferon alfa-2b in interferon-naïve patients with chronic hepatitis C: a randomized, controlled study

    Alimentary Pharmacology & Therapeutics

    Volume 26, Issue 3, August 2007, Pages: 369–376, R. BRUNO, P. SACCHI, C. SCAGNOLARI, F. TORRIANI, L. MAIOCCHI, S. PATRUNO, F. BELLOMI, G. FILICE and G. ANTONELLI

    Version of Record online : 29 MAY 2007, DOI: 10.1111/j.1365-2036.2007.03392.x

  19. Extended peginterferon plus ribavirin treatment for 72 weeks versus standard peginterferon plus ribavirin treatment for 48 weeks in chronic hepatitis C genotype 1 infected slow-responder adult patients

    Intervention Review

    The Cochrane Library

    Lior H Katz, Hadar Goldvaser, Anat Gafter-Gvili and Ran Tur-Kaspa

    Published Online : 12 SEP 2012, DOI: 10.1002/14651858.CD008516.pub2

  20. eGFR decrease during antiviral C therapy with first generation protease inhibitors: a clinical significance?

    Liver International

    Volume 35, Issue 1, January 2015, Pages: 71–78, Véronique Loustaud-Ratti, Annick Rousseau, Paul Carrier, Chanlina Vong, Tristan Chambaraud, Jérémie Jacques, Marilyne Debette-Gratien, Denis Sautereau and Marie Essig

    Version of Record online : 27 JUL 2014, DOI: 10.1111/liv.12631